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TUTORIAL
Use of Modeling and Simulation in the Design and
Conduct of Pediatric Clinical Trials and the Optimization
of Individualized Dosing Regimens
C Stockmann1, JS Barrett2, JK Roberts1 and CMT Sherwin1*
Mathematical models of drug action and disease progression can inform pediatric pharmacotherapy. In this tutorial, we explore
the key issues that differentiate pediatric from adult pharmacokinetic (PK) / pharmacodynamic (PD) studies, describe methods to
calculate the number of participants to be enrolled and the optimal times at which blood samples should be collected, and
therapeutic drug monitoring methods for individualizing pharmacotherapy. The development of pediatric-specific drug dosing
dashboards is also highlighted, with an emphasis on clinical-relevance and ease of use.
CPT Pharmacometrics Syst. Pharmacol. (2015) 4, 630–640; doi:10.1002/psp4.12038; published online 13 November 2015.
KEY ISSUES IN PEDIATRICS
Pediatrics remains a largely untapped area of opportunity for
pharmacometric analyses. Consequently, pediatric pharma-
cokinetic (PK) and pharmacodynamic (PD) studies are
needed to inform dosing selection for efficacy trials and for
establishing dosing recommendations for pediatric subpopu-
lations. The two biggest obstacles are the lack of compelling,
pediatric-specific biomarkers and ill-defined or absent pediat-
ric disease progression measures. Additionally, there is wide
variation in how basic study design constructs (e.g., sample
sizes, sampling strategies, and dosing regimens) are imple-
mented in pediatric clinical trials and the degree to which
modeling and simulation are used to support these critical
study design elements. Dosing objectives are intimately tied
to the assumptions of disease similarity between pediatric
and adult indications, which is rarely demonstrated. The
question of similarity between adult and pediatric disease is
at the top of the US Food and Drug Administration’s (FDA)
decision tree and the answer to this question dictates the
regulatory path that is taken, which may involve an exposure-
equivalence analysis, PK/PD, and/or efficacy/safety trials.1,2
Similarly, modeling and simulation objectives are focused
on recommending doses that are adequately demonstrated
to be similar to those established in adults (an equivalence
approach) or those which allow mapping of the exposure–
response relationship to suspected target activity thresholds.
In either case, considerations of size, maturation, organ func-
tion, and disease state must be incorporated within the testing
scenario to support dosing targets across regulatory-defined
age strata. This hinges on an appropriate sample size (in total
and within each age strata) and a PK/PD sampling strategy
that is optimized through simulation and incorporates alterna-
tive constructs, which are appropriate for each pediatric sub-
population. The basic tenet for the approach we will outline
herein is to illustrate how modeling and simulation methods
can be used to design a pediatric-specific clinical trial that
meets the performance objectives of the trial. More specifi-
cally, we will also demonstrate how to design a pediatric clini-
cal trial with an appropriate number of subjects to ensure
adequate statistical power with a sufficient number of opti-
mally timed samples to yield PK/PD parameters that are
unbiased and precise, which can then be used to facilitate the
creation/revision of drug dosing recommendations. Addition-
ally, for drugs with narrow therapeutic windows, modeling and
simulation methods are presented to allow clinicians to
develop individualized dosing regimens.
POWER AND SAMPLE SIZE CALCULATIONS
Power and sample size calculations are vitally important for
pediatric trials, as most drug development programs only con-
duct a single pediatric trial, the results of which are then used
to justify dosing recommendations for future studies and reg-
ulatory approval.3 Several methods for defining an appropri-
ate sample size for pediatric population PK studies have
been proposed, each of which is associated with relative
strengths and weaknesses.4–7 The most well-known
approach was put forth by the FDA in 2012.3 This approach
aims to precisely estimate PK parameters (e.g., clearance
and volume of distribution). The regulatory requirement that
evolved from this approach states that a pediatric trial “must
be prospectively powered to target a 95% confidence interval
within 60-140% of the geometric mean estimates of clear-
ance and volume of distribution [. . .] in each pediatric sub-
group with 80% power.”3 Pediatric subgroups are most
commonly derived from stratifications based on age; however,
other physiologic (e.g., weight) or pathophysiologic (e.g., rate
of disease progression) factors that influence the exposure–
response profile should also be considered to ensure that the
sample size is appropriate given the trial’s objectives. In three
examples put forth by the FDA, including two antibiotics and
one sympatholytic drug, the following age groups have been
used: 3 to <6 months, 6 to <12 months, 1 to <2 years, 2 to
<6 years, 6 to <12 years, and 12 to 18 years.3
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The first step in performing a power and sample size calcu-
lation for a pediatric population PK or PD study is to define
the objective(s) of the trial (e.g., assess individual PK param-
eters, including: an evaluation of absorption processes,
assessments of drug distribution, quantification of the rate/
extent of metabolism and excretion, and determination of
whether different dosing regimens are needed to account for
developmental or maturational changes). After the primary
objective has been established it is then incumbent on the
study design and modeling and simulation teams to define the
subgroups that will be evaluated. For particularly vulnerable
patient populations it may be necessary to consider reducing
the number of samples collected from each participant or use
alternative sampling methods (e.g., a heel stick on a newborn
as opposed to placing an indwelling line). When defining these
subgroups, the investigators should also explore logistical
considerations that may preclude certain study designs. For
example, a PK study involving serial sampling every few hours
over a 5-day period may prove to be unduly burdensome for
children attending school. Additionally, opportunistic or obser-
vational sampling schemes should be considered when possi-
ble to minimize participant discomfort and improve retention.
As an example, we recently enrolled children who were under-
going an outpatient surgical procedure and obtained blood
samples after the child had been anesthetized, which allowed
us to minimize the discomfort to the patient and also allowed
easy access to the systemic circulation due to the placement
of a peripheral catheter for routine anesthesia.
When the research objectives and the subgroups have been
defined, the investigators should next consider whether a non-
compartmental analysis (NCA) or a population PK analysis is
more appropriate. Although this tutorial is focused on popula-
tion PK modeling, we have provided R code in Appendix 1
that can be used to generate sample size vs. power compari-
sons such as that depicted in Figure 1 using an NCA
approach. As described above, power reflects the probability of
achieving a 95% confidence interval within 60–140% of the
geometric mean estimate for each pharmacokinetic parameter.
For population PK analyses, sample size vs. power can
be compared in a similar manner. Allometric scaling is fre-
quently used to scale adult PK parameters to young chil-
dren and vice versa, so we shall consider an example in
which the objective is to precisely define clearance for drug






where WTind refers to the weight of the individual patient,
which has been standardized to a typical adult value of
70 kg. The allometric coefficient (Coefallo) can be fixed to a
certain value (e.g., 0.75) or it can be estimated.8,9 By taking
the logarithm of CL (LCL) we then derive the linear function:





Using this covariate model structure we can now use esti-
mates from the literature or past experiments as inputs within
our sample size code to calculate the power of the trial with
varying numbers of subjects as shown in Appendix 2.
OPTIMAL SAMPLING TIMES
The selection of optimal sampling times is critical when con-
ducting pediatric population PK/PD studies. Attention to the
design of the sampling strategy can reduce the cost of the
trial and the burden imposed on the study’s participants.
One example of a design metric used to evaluate sampling
strategies is the D-optimality criterion.10 D-optimality
assumes that the structural PK model is known and that reli-
able data exist regarding the size and distribution of the
parameters.7 This means the optimal design can only be as
accurate as the parameters used to determine the optimal
sampling times. However, in situations where limited data
exist for the population of interest, initial PK parameter esti-
mates may be derived from adult studies or, in some cases,
animal models, which may be the best place to start. From
these initial studies, the variance of the estimated parame-
ters should also be identified, as these will be necessary
when determining the optimal sampling time points.
Several open source software programs are freely avail-
able for use in developing optimal sampling times for popu-
lation PK studies, some of which include: PFIM/PFIMOPT
(developed at INSERM, Universitè Paris 7, France)11,12;
PopDes (developed at the University of Manchester, United
Kingdom)13; PopED (developed at Uppsala University, Swe-
den)14; POPT/WinPOPT (developed at the University of
Otago, New Zealand)15; and ADAPT (developed at the Uni-
























Figure 1 A graphical comparison of sample size vs. power (the
probability of deriving a PK parameter estimate with a 95% confi-
dence interval within 60–140% of the geometric mean estimate)
for a hypothetical drug with a standard deviation of 0.45 and 0.35
for clearance (depicted in red) and volume of distribution (depicted
in blue), respectively, using a noncompartmental approach.




detailed discussion of optimal design, including the advan-
tages and disadvantages associated with different methods
and software programs, can be found in detailed reviews by
Roberts et al. and Nyberg et al.17,18
To explore the power of optimal design theory we will use
data from a recently completed phase I PK and safety trial of
darbepoetin alfa, which is used in the treatment of hypoxic-
ischemic encephalopathy.19 This study involved 30 neonates
and employed sparse sampling techniques to generate a
total of 95 serum concentrations.20 A population PK analysis
indicated that a one-compartment model provided the best fit
to the data; however, it was unclear if the sampling times
employed in this small pilot study were optimal and should be
recommended for use in an upcoming phase II/III trial. Addi-
tionally, it was unclear if the one-compartment model was the
best descriptor of darbepoetin alfa PK in neonates or
whether the data were too sparse and precluded fitting a
more appropriate two-compartment model. Optimal design
techniques can be used to answer these questions.
The software programs ADAPT 5 and PFIM were used
to design an optimal sampling strategy for a future phase
II/III darbepoetin alfa neonatal trial in Appendices 3 and 4,
respectively.16,21 For this study, the design originally had
four sampling times, which have been used as initial inputs
in this example to optimize the sampling times for both dar-
bepoetin alfa clearance and volume of distribution. As the
drug is administered intravenously we did not seek to opti-
mize the absorption rate constant Ka.
For this example, two optimal sampling times were identi-
fied, which is in agreement with D-optimal design theory,
which states that a single optimal time will exist for each
parameter to be optimized.22 We sought to estimate darbe-
poetin alfa clearance and volume of distribution and the D-
optimal design suggested obtaining two samples at nearly
time 0 and at 57 hours postdose. However, since it is diffi-
cult to obtain a concentration immediately after a drug has
been administered (particularly if the same venous line
must be used for both dosing and sample collection), it
may be appropriate to fix the first sample collection at 1
hour. Additionally, it may be easier to obtain a sample at 60
hours postdose as opposed to 57 hours. In this case, we
would also fix the last sampling time at 60 hours postdose.
As mentioned previously, it is unclear if darbepoetin alfa
PK in this neonatal population are best described using a
one- or a two-compartment model. Using previously pub-
lished data from adults, it is possible to design a two-
compartment optimal design (Figure 2).23 In this scenario,
the 1- and 60-hour sampling times were fixed based on the
results of the one-compartment model (blue boxes) and the
other two timepoints were optimized to precisely estimate
the intercompartmental clearance and the volume of distri-
bution in the peripheral compartment (red boxes).
As there is uncertainty in the PK model that best describes
the kinetic profile of this drug in neonates, it may be appropri-
ate to consider employing an adaptive design in the phase II/
III clinical trial, whereby four sampling times are initially used
for the first half of the patients who are enrolled. Then an
interim PK analysis may be performed to determine if a one-
or a two-compartment model best describes darbepoetin alfa
PK in this population. At this point, if it is determined that a
one-compartment model performs well then the remaining
50% of the patients who will be enrolled could have only two
samples obtained for the purpose of estimating darbepoetin
alfa PK parameters. Alternatively, if a two-compartment model
fits the data better the trial may proceed, with the remaining
50% of patients having four samples collected at the optimal
sampling times defined above as determined by D-optimality.
For additional information regarding adaptive designs in popu-
lation PK studies see Foo and Duffull and Dumont et al.24,25
DATA ANALYSIS
Pharmacokinetics
The development of a population PK model can be broadly
divided into two stages. The first stage concentrates on the
selection of an appropriate structural model (e.g., one-
compartment with first-order absorption and elimination) and
the second stage focuses on characterizing relationships
between covariates and the PK parameters of interest. The
selection of an appropriate structural model for pediatric PK
studies is similar to the approach used in adult PK studies,
albeit with the caveat that simpler, compartmental models are
often favored for pediatric studies due to the limited number
of blood samples that can be obtained from small children.
The majority of the differences in pediatric PK modeling arise
when developing the covariate model structure.
Covariate models are used to define the sources of PK vari-
ability within a population.26 For children, normal developmental
processes and pathophysiologic changes can complicate
efforts to develop uniform dosing recommendations.27 In partic-
ular, aspects of growth and development associated with differ-
ences in body size and age can be investigated when building
a covariate model and may be useful in explaining the predict-
able components of between-subject variability.27 As mentioned
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Figure 2 Predicted darbepoetin alfa concentration (lg/mL) vs.
time (hours) profile for neonates undergoing hypothermia for the
treatment of hypoxic-ischemic encephalopathy. Two D-optimal
sampling times were identified at 1 and 60 hours (represented
by blue boxes) when designing a neonatal trial that seeks to
describe darbepoetin alfa PK with a one-compartment model.
However, if a two-compartment model is used four D-optimal
sampling times were identified at 1, 21, 60, and 90 hours (repre-
sented by blue and red boxes).
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differences in size.8,28 Allometric scaling is frequently used
when developing population PK models to extend data from
animal models to derive extrapolated human PK parameter
estimates and to scale adult PK parameters to children.29 The
decision to fix the allometric coefficient (e.g., 0.75 for clear-
ance) or have the model estimate the allometric coefficient
should be guided by an evaluation of the predictive perform-
ance of the model, as described by Krekels et al.30 Age is also
commonly used to describe the maturation of drug clearance
mechanisms (e.g., maturation of renal function).8 Several quan-
titative approaches have been used to model the maturation of
drug clearance processes, including: linear, exponential, first-
order, and sigmoidal models.31 To demonstrate the application
of these methods in the development of a pediatric
population PK model, we developed a simulated dataset with a
range of weights and ages (Figure 3). The R code used to
develop this dataset is featured in Appendix 5.
This dataset features sigmoidally correlated postmenst-
rual age (defined as the period ranging from the first day of
the last menstrual period through the date of assessment)
and weight values that were adapted from the US Centers
for Disease Control and Prevention’s (CDC) infant growth
curves.32,33 If our drug of interest is known to be primarily
eliminated through renal mechanisms, then we may con-
sider employing a variable slope sigmoidal model, such as
that described by Anderson et al.,31 which incorporates a





In this model, the maturation of renal clearance is described
as a function of postmenstrual age (PMA), the PMA at which
50% of adult clearance is reached (TM50), and a Hill coeffi-
cient (Hill) that governs the shape of the sigmoidal curve. This
sigmoidal maturation model can be implemented in the nonlin-
ear mixed effects modeling program NONMEM as:
$PROBLEM Sigmoidal maturation example
$INPUT C ID TIME AMT DV MDV RATE WT PMA
; ID = Subject identifier
; TIME = Time (measured in hours)
; AMT = Dose amount (mg)
; DV = Drug concentration (mg/L)
; MDV = Missing dependent variable
; RATE = Infusion rate (mg/hr)
; WT = Weight (kg)




TVCL = THETA(1)*(WT/70)**0.75 * (1/
(1+(PMA/THETA(3))**(-(THETA(4)))))
CL = TVCL * EXP(ETA(1))
TVV = THETA(2) * (WT/70)**1.0









0.5 ; THETA1 (Clearance coefficient)
2.5 ; THETA2 (Volume coefficient)
40 ; THETA3 (Maturation midpoint)
4 ; THETA4 (Hill coefficient)
$OMEGA
0.1 ; ETA1 (Clearance)
0.1 ; ETA2 (Volume)
$SIGMA
0.05 ; SIGMA1 (Proportional error)
1.0 ; SIGMA2 (Additive error)
$SIM (123456) NSUB=24
$TABLE ID TIME AMT MDV TVCL CL TVV V TM50 HILL
SIM IPRED CWRES NOPRINT ONEHEADER FILE=sim.fit
This sigmoidal clearance maturation model has been
used to describe vancomycin clearance in preterm and full-
term neonates.34,35 For vancomycin, it was determined that
49% of the variability in clearance was explained by body
weight, 18% by PMA, and 14% by renal function (as meas-
ured by serum creatinine concentration).34 The use of this













Figure 3 Correlated postmenstrual age (weeks) vs. weight (kg)
values for a population of 200 simulated children.




between PMA and vancomycin clearance also allowed the
investigators to scale data from their population of preterm
neonates to adults, which would not be possible in reverse
without accounting for the maturation of renal clearance
mechanisms.34 It is worth noting that the sigmoidal function
featured above in Eq. 3 is an example that may be applied
to other maturational and developmental processes.
Decreasing variability in PK parameters improves our ability
to develop dosing regimens that reliably achieve therapeutic
targets. For vancomycin, explaining 81% of the variability in
clearance among neonates using a combination of body
weight, PMA, and serum creatinine concentrations allows for
more accurate estimation of the probability of achieving a ratio
of the 24-hour area under the concentration vs. time curve to
the minimum inhibitory concentration (AUC24/MIC) 400,
which has been associated with improved clinical and micro-
biological outcomes in adults with lower respiratory tract
infections caused by the methicillin-resistant bacterium Staph-
ylococcus aureus.36 Additionally, more accurate estimation of
vancomycin clearance allows us to develop dosing regimens
that are less likely to result in potentially toxic trough concen-
trations.35,37 Recently, using an externally validated neonatal
vancomycin population PK model that incorporates body
weight, PMA, and serum creatinine concentrations, we found
that the percentage of neonates predicted to achieve a thera-
peutic AUC24 was 100% using the population PK model, as
compared with 39–51% for dosing regimens recommended in
nomograms published by the British National Formulary
(based on NeoFax dosing recommendations) and the Ameri-
can Academy of Pediatrics’ Red Book.38–40 Moreover, the pro-
portion of neonates predicted to have a potentially toxic trough
concentration was 0% using the population PK model, as com-
pared with 0–5% using the NeoFax and Red Book dosing
nomograms.38,39 In aggregate, these findings reveal that
externally validated pediatric-specific population PK models
can be used to reliably inform treatment decisions at the level
of an individual patient, thereby improving patient care.
Pharmacodynamics
Determining the appropriate metric for assessing the ade-
quacy of a patient’s response to therapy is one of—if not
the most—challenging aspects of pharmacometrics. The
challenge is often compounded in pediatrics, in which direct
extrapolations of adult efficacy measures may not be possi-
ble or appropriate.41,42 Nevertheless, this is a vital compo-
nent of pediatric clinical pharmacology for which modeling
and simulation are that much more important due to the
need to assess a range of physiologic markers of drug
activity, often with limited data.
A motivating example may be found in the monitoring of
human cytomegalovirus (CMV) viral loads among children who
have undergone solid organ transplantation and received an
organ from a donor who was CMV seropositive.43 It is standard
clinical practice to monitor the effectiveness of prophylactic
therapy with valganciclovir by monitoring a patient’s CMV load
using quantitative polymerase chain reaction (qPCR).44 The
effectiveness of valganciclovir prophylaxis can then be varied
using simulation to determine thresholds below which therapy
will be ineffective and CMV is disseminated throughout the
bloodstream (viremia) as compared with thresholds above
which therapy is effective and CMV replication is effectively
suppressed, thereby preventing breakthrough viremia.
When developing mechanistic (indirect) PD models it is
helpful to consider a drug’s mechanism of action. In this
example, our drug of interest (valganciclovir) is an orally
administered L-valine ester prodrug of ganciclovir.45 Val-
ganciclovir is rapidly converted to ganciclovir by intestinal
and liver esterases, after which it undergoes phosphoryla-
tion to ganciclovir triphosphate, which inhibits viral DNA
polymerase and slows DNA elongation.46 This inhibitory
effect on viral replication can be incorporated within a basic
model of viral infection such as that featured in Figure 4.
Using a viral dynamics model adapted from Perelson,47
target cells (T) are produced at a constant rate (k) and are
susceptible to infection by CMV virions (V). This infection
Figure 4 A visual schematic of the inhibitory effects of ganciclovir (and its oral prodrug valganciclovir) on human cytomegalovirus
(CMV) replication. In this model, target cells (T) are produced at a constant rate (k), and die at a constant rate (d [not shown]). Target
cells are infected by CMV virions (V) at rate k (the infection rate). Infected cells (I) die at a constant rate (d) and produce q virions per
cell, which are then cleared from the body at rate c.
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process is governed by the infection rate k. Following infec-
tion, infected cells (I) produce new CMV virions at rate q
and die at rate d per cell. Virions are cleared from the body
at rate c per virion. Although not shown in the figure, target
cells also die at a rate d per cell. The inhibitory effect of
valganciclovir (and its active metabolite ganciclovir triphos-
phate) on viral replication is illustrated in red.
Using this model, we can simulate the rate of viral growth
over a 150-day period of prophylaxis at varying valganciclo-
vir effectiveness thresholds. Longitudinal CMV loads can be









5 12eGANð Þ qI2cV (6)
where valganciclovir prophylaxis (eGAN) is assumed to be
0%, 20%, 40%, 50%, 60%, and 70% effective in suppress-
ing CMV replication. The data may then be visualized
for each of these scenarios as shown in Figure 5. The
lower limit of quantification for the CMV qPCR assay is
150 copies/mL, which is denoted by the gray horizontal line.
These simulations reveal that breakthrough CMV viremia
among pediatric solid organ transplant recipients is unlikely to
occur when valganciclovir prophylactic regimens achieve
60% suppression of viral replication. It is therefore reasona-
ble to expect that dosing modifications may be based on physi-
ological and pathophysiological factors that influence
ganciclovir and valganciclovir PK, which have the potential to
influence the concentration–effect relationship. Additionally, it
should be noted that in this example age-dependent effects on
the response to ganciclovir/valganciclovir were not modeled;
however, such effects may exist for other drugs and should be
explored in the model-building process. Alternative scenarios
may be explored using the R code provided in Appendix 6.
INDIVIDUALIZED DOSING
After developing a population dosing regimen that incorpo-
rates patient characteristics (covariates) that significantly
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Figure 5 Simulations of human cytomegalovirus (CMV) loads over 150 days with a starting inoculum of 1 3 1024 virions. Varying thresholds
of valganciclovir’s effectiveness are presented with colored lines. With the initial conditions specified in Appendix 6, this simulation reveals that
if a valganciclovir prophylaxis regimen achieves60% suppression of CMV replication, breakthrough viremia is unlikely to occur.




influence a drug’s pharmacokinetic parameters it is possible
that additional unmeasured factors may contribute to signifi-
cant variability in the observed effectiveness of the regi-
men. In situations such as these it may be necessary to
measure drug concentrations from each patient receiving
treatment to ensure that they achieve therapeutic and safe
drug exposure levels.
Therapeutic Drug Monitoring
If the drug under investigation features a narrow therapeu-
tic window and displays highly variable pharmacokinetics
in the patient population being studied, it may be neces-
sary to measure drug concentrations in real time and alter
the dosing regimen accordingly to target a therapeutic and
safe range of concentrations—a practice known as thera-
peutic drug monitoring.48 Therapeutic drug monitoring is
built on the strength of previously defined exposure–
response relationships, which describe how changes in
drug exposure affect selected measures of efficacy and/or
tolerability.49,50 When the best PK predictor of the
response to therapy is unknown or insufficient validation of
targets has been performed, therapeutic drug monitoring is
of limited utility. Consequently, well-designed pediatric pop-
ulation PK studies are invaluable, as the results of these
trials may be used to develop targets that can be applied
clinically to individualize therapy for drugs with narrow ther-
apeutic windows.51,52
A motivating example of pediatric therapeutic drug
monitoring can be found in the drug busulfan, which is an
alkylating agent that is commonly used in conditioning regi-
mens for hematopoietic stem cell transplantation
(HSCT).53 In previous studies, an AUC of 3.6–5.4 mg*hr/L
has been shown to improve engraftment rates and has
been associated with a decreased risk for drug-related tox-
icity (e.g., mucositis and sinusoidal obstruction syn-
drome).54–56 High between-subject variability in busulfan
pharmacokinetics makes it challenging to reliably achieve
this target with the FDA-approved dose of 1.1 mg/kg for
children 12 kg and 0.8 mg/kg for children >12 kg.57 To
ensure that children who are treated with busulfan achieve
therapeutic and safe levels of drug exposure, busulfan con-
centrations are often measured as part of routine clinical
care. Abnormally low AUCs are then used as justification to
increase the busulfan dose and abnormally high AUCs
prompt dose reductions.
Long-Boyle et al. recently evaluated 90 pediatric and
young adult patients who had undergone an HSCT and
received busulfan.53 Busulfan was administered at the
FDA-approved dose as a 2-hour infusion, every 6 hours, for
a total of 16 doses. Blood samples were drawn for popula-
tion PK modeling at 2, 2.25, 2.5, 3, 4, 5, and 6 hours after
the first dose was administered. If dosing modifications
were made, a second and third set of drug concentrations
were obtained around the 9th and 13th doses, respectively.
Using these doses, sampling times, and the population PK
parameters reported in their analysis, we have recreated a
simulated version of their study in NONMEM using the fol-
lowing code:
$PROBLEM Busulfan therapeutic drug monitoring
example
$INPUT C ID TIME AMT DUR DV MDV WT AGE
; ID = Subject identifier
; TIME = Time (measured in hrs)
; AMT = Dose amount (mg)
; DUR = Infusion duration (hrs)
; DV = Drug concentration (mg/L)
; MDV = Missing dependent
variable
; WT = Weight (kg)
; AGE = Age (yrs)
$DATA CPT_PSP_TUTORIAL_DATA_5.CSV IGNORE=C




V1 = THETA(1) * EXP(ETA(1))
S1 = V1
VM = THETA(2)
KM = THETA(3) * EXP(ETA(2))
CL = ((VM * 1000/KM) * (WT/22)**0.75









Y = IPRED + SD * EPS(1) * (1 + IPRED
* CV2SD)
$THETA
15.7 ; THETA1 (Volume coefficient)
28.96 ; THETA2 (Vmax coefficient)
6704 ; THETA3 (Km coefficient)
0.148 ; THETA4 (Proportional residual
error [SD])
47 ; THETA5 (Additive residual error
[CV])
$OMEGA
0.08 ; ETA1 (Volume)
0.09 ; ETA2 (Km)
$SIGMA
1 FIX ; SIGMA1 (Eps1)
$SIM (123456) NSUB=1
$TABLE ID CL V1 VM KM AUC WT AGE FIRSTONLY
NOPRINT ONEHEADER FILE=sim.fit
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In this example, the busulfan AUC is derived for each
subject by dividing the administered dose by the individual-
predicted clearance estimate. Of the 10 simulated subjects,
3 (30%) had an AUC within the target range of 3.6–
5.4 mg*hr/L. The remaining seven (70%) subjects had
busulfan AUCs that were below the lower end of the thera-
peutic window, which suggests that this dosing regimen
may be insufficient. Based on these findings, Long-Boyle
et al.53 developed a user-friendly Excel tool that calculates
the recommended dose based on an individual’s clearance
estimate and the desired AUC target:
Dose mgð Þ5AUCtarget mghr=Lð ÞCLindividual L=hrð Þ (7)
Using this equation, the authors found that the model
recommended busulfan doses that were 25% higher
than those recommended on the package insert.53 In a
prospective evaluation, the authors observed that 81% of
the 21 children who received the model recommended
busulfan dose achieved the therapeutic target as com-
pared with 52% of the 90 children who received the busul-
fan dose recommended in the package insert (P 5 0.02).53
Moreover, the proportion of children with subtherapeutic
busulfan exposure decreased from 42% with conventional
dosing to 10% with model-recommended dosing.53
Dashboard systems
Optimal pharmacotherapy is implicitly an endeavor in per-
sonalized medicine. While the caregiver inherits prescribing
information from the drug label and the scientific literature,
these are generally static sources of information constructed
from somewhat idealized patients who consented to partici-
pate in earlier clinical trials. Likewise, the experience of the
prescribing community is often empirically based and simply
reflects the current practice as opposed to the best practice.
The situation is obviously worse for children, given the heavy
reliance on extrapolation from adult studies and the limited
clinical evidence documenting the safety and effectiveness
of drugs prescribed to children. The “management” of drug
therapy falls well outside of simple dosing considerations
based on size or maturation-based scaling. In clinical prac-
tice, the dosing regimen may need to accommodate drug–
drug interactions or the potential for interactions with other
concomitant medications.58 Additionally, the intended regi-
men may need to be indexed and/or adjusted based on the
monitoring of drug concentrations, biomarkers, or clinical
signs and symptoms.59 The concept of a dashboard, then, is
an interface for relevant patient-centric readouts that is cur-
rent and critical to the holistic view of the patient.
The goal of a drug dashboard is to provide a platform for
displaying current, relevant indices of patient well-being in
Table 1 Dashboard selection categories used to derive objective and subjective rankings for potential drug candidates at a children’s hospital
Rank Criterion
Drug utilization
1 Days of therapy per 1,000 hospital days
2 Total pharmacy costs (acquisition 1 administration)
Medical need
1 Disease/condition with few pharmacotherapy options
2 Disease/condition with few pharmacotherapy options for children
3 Disease/condition with few pharmacotherapy options for a specific pediatric subpopulation (e.g., critically ill)
4 Target agent requires titration to effect without acceptable dosing guidance
5 Poor outcomes associated with subtherapeutic exposure
6 Toxic events associated with exposure
7 Toxicity associated with chronic administration (exposure or dose intensity)
Guidance outcome value
1 Established relationship between activity (or efficacy) and exposure in children
2 Established relationship between safety (or adverse events) and exposure in children
3 Available PK or PK/PD model that is correlated with clinical outcomes in children
4 Established relationship between activity (or efficacy) and exposure in adults
5 Established relationship between safety (or adverse events) and exposure in adults
6 Available PK or PK/PD model that is correlated with clinical outcomes in adults
Dashboard viability
1 Availability of a clinical champion (e.g., physician, pharmacist) to aid in designing the dashboard, optimizing its
workflow, and encouraging its use
2 Availability of a pharmacometrician/clinical pharmacologist to design the model that will be used to inform pediatric
dosing
3 Required data available in existing electronic medical records system(s) or data warehouse
4 A PK or PK/PD model that provides a forecasting routine and/or visualization tools that are adequately specified
with respect to the dashboard’s functional requirements for clinical use
5 Software that is capable of integrating multiple data sources and modeling software outputs, which ports the
results into a user-friendly clinical interface
6 Adequate information technology (IT) support and programming resources available




response to longitudinal trends in pharmacotherapy. While
there may be flexibility in the views that the caregiver
selects or assesses, it is assumed that the dashboard is a
centralized environment for key response elements. It is not
principally a place to search for answers, document proc-
esses, or do research. While one element of the dashboard
environment could indeed include scenario testing, particu-
larly around the choice of pharmacotherapy options (e.g.,
drug selection, dosages), these answers must come quickly
and without a steep user learning curve. Similarly, it is
assumed that the source data populating the dashboard
are of high quality and in a form to be quickly viewed, con-
sumed, modeled, or simulated based on the desired func-
tionality. Patient-centric views, decision support logic, and
compliance with institutional protocols should be properly
vetted, with clinical champions representing the end-user
community. Moreover, any models and/or algorithms used
to support treatment decisions must be properly validated
with external data that are representative of the intended
population of interest. These are essential elements of
dashboard development and not merely “nice to haves”
(Table 1).58–60
There are several examples of patient-specific dosing
guidance/decision support systems that rely on therapeutic
drug monitoring-based procedures. However, in actuality,
very few dashboard systems are currently in production,
although several are under evaluation. Dashboards are
widely implemented in business intelligence software pro-
grams, which has the potential to hasten their development
for clinical applications (e.g., Cognos, Tableau, etc.). The
drugs targeted for dashboard systems are typically based
on medical need, such that drugs with narrow therapeutic
indices are often selected, particularly when the clinical
benefit of therapeutic drug monitoring has been well estab-
lished (e.g., mycophenolate, tacrolimus, methotrexate). For
the pediatric population, we developed a high-dose metho-
trexate dashboard that is ultimately envisioned as a web-
based environment that will provide global users with the
ability to: (i) register their patient data; (ii) view dosing
transactions based on institution/caregiver-specific criteria
in real time; (iii) forecast future outcomes; and (iv) adhere
to protocol-specific dosing guidances (Figure 6).61
CONCLUSION
In the past, the safety and effectiveness of many prescription
medications were not evaluated in children.62 Fortunately,
Figure 6 A dashboard for pediatric methotrexate dosing is envisioned that leverages demographic, clinical, and laboratory data to build
a population PK model that rapidly generates individualized methotrexate dosing recommendations within an Internet browser.
Use of Modeling and Simulation in the Design
Stockmann et al.
638
CPT: Pharmacometrics & Systems Pharmacology
following the enactment of the FDA Modernization Act of
1997, the Best Pharmaceuticals for Children Act, the Pediat-
ric Research Equity Act, and other regulatory initiatives, this
paradigm has shifted, such that drugs that are not studied in
children are now the exception rather than the norm.63–66
However, there is a pressing need to ensure that the trials
that are being conducted today are designed and analyzed
appropriately, thereby generating high-quality data that can
be used to meaningfully improve pediatric pharmacotherapy.
When designing pediatric PK/PD studies, it should be
noted that the careful selection of an appropriate sample
size and optimal sampling times depends heavily on the
structure of the PK/PD model and the estimated variance
of each of the parameters that will be estimated in the trial.
If data to support these inputs for the target population
(e.g., neonates or critically ill children) are lacking, then an
adaptive design should be considered. Such an approach
incorporates one or more interim PK analyses that are
used to reconfigure the selection of sampling times and/or
the number of participants to ensure that the trial’s objec-
tives are efficiently met for the target population.
At the level of an individual patient, population PK/PD
studies are particularly valuable, as they can be used to
establish targets that are reliably associated with improved
clinical outcomes. Often such targets are extrapolated from
the adult literature; however, where possible, pediatric stud-
ies should be encouraged to assess the similarity between
pediatric and adult indications, as this is rarely proven.
Models of drug action and disease progression have been
underutilized as ways of addressing dosing questions for
pediatric patients. Mathematical drug/disease models paired
with therapeutic drug monitoring are the most credible
means available to inform clinical decision making. Such
techniques force our clinical and pharmacometrics col-
leagues alike to make conscious decisions regarding which
patient covariates influence the dose–exposure–response
relationship. In this way, models help to make the complex
biology of a disease and the physiological processes govern-
ing drug disposition more manageable and allow us to scruti-
nize and debate model-building and clinical decision-making
processes with transparency. Although no single “ideal”
method exists for developing pediatric PK/PD models, the
methods described in this tutorial highlight several key fea-
tures that are likely to be broadly generalizable and may be
molded to fit other clinical scenarios as needed.
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